High-throughput scanning of breast tumor surgical specimens for low-level mutations.

about

High-throughput scanning of breast tumor surgical specimens for low-level mutations.

Item

http://www.wikidata.org/entity/Q54638714

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

High-throughput scanning of breast tumor surgical specimens for low-level mutations.

@en

High-throughput scanning of breast tumor surgical specimens for low-level mutations.

@nl

type

Item

label

High-throughput scanning of breast tumor surgical specimens for low-level mutations.

@en

High-throughput scanning of breast tumor surgical specimens for low-level mutations.

@nl

prefLabel

High-throughput scanning of breast tumor surgical specimens for low-level mutations.

@en

High-throughput scanning of breast tumor surgical specimens for low-level mutations.

@nl

P1476

High-throughput scanning of breast tumor surgical specimens for low-level mutations.

@en

P2093

Fengfei Wang

http://www.w3.org/2001/XMLSchema#string

G Mike Makrigiorgos

http://www.w3.org/2001/XMLSchema#string

Jin Li

http://www.w3.org/2001/XMLSchema#string

Lilin Wang

http://www.w3.org/2001/XMLSchema#string

Manjit Kaur

http://www.w3.org/2001/XMLSchema#string

Penny Zhu

http://www.w3.org/2001/XMLSchema#string

Wei-Hua Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Emerging molecular markers of cancer.

Mutator phenotypes in human colorectal carcinoma cell lines.

How many mutations does it take to make a tumor?

Ligation of a primer at a mutation: a method to detect low level mutations in DNA.

DNA amplification method tolerant to sample degradation.

Inverse PCR-based RFLP scanning identifies low-level mutation signatures in colon cells and tumors.

Increased transversions in a novel mutator colon cancer cell line.

Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells.

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.

P304

810-816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1515/CCLM.2005.136

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16201889

http://www.w3.org/2001/XMLSchema#string